Pharmaceutical

Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…

12 months ago

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies…

12 months ago

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused…

12 months ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced…

12 months ago

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

BioJet device exceeded performance targets for delivery of collaborator AstraZeneca’s molecule in preclinical studySAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE)…

12 months ago

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alimera Sciences Names Elliot Maltz as Chief Financial Officer Elliot Maltz, CFO of Alimera Sciences ATLANTA, Jan. 02, 2024 (GLOBE…

12 months ago

Court Finds Corcept Therapeutics’ Patents Not Infringed

MENLO PARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the…

12 months ago

Anavex Life Sciences Provides an Update on Rett Syndrome Program

Anavex Announces Topline Results from Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome Validation from Real World Evidence (RWE)…

12 months ago

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and…

12 months ago

Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients

SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

12 months ago